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Abstract
Nucleotide pyrophosphatase phosphodiesterase 1 (NPP1) is required for the conversion of extracellular ATP into inorganic
pyrophosphate (PPi), a recognised inhibitor of hydroxyapatite (HA) crystal formation. A detailed phenotypic assessment of a
mouse model lacking NPP1 (Enpp1
2/2) was completed to determine the role of NPP1 in skeletal and soft tissue
mineralization in juvenile and adult mice. Histopathological assessment of Enpp1
2/2 mice at 22 weeks of age revealed
calcification in the aorta and kidney and ectopic cartilage formation in the joints and spine. Radiographic assessment of the
hind-limb showed hyper-mineralization in the talocrural joint and hypo-mineralization in the femur and tibia. MicroCT
analysis of the tibia and femur disclosed altered trabecular architecture and bone geometry at 6 and 22 weeks of age in
Enpp1
2/2 mice. Trabecular number, trabecular bone volume, structure model index, trabecular and cortical thickness were
all significantly reduced in tibiae and femurs from Enpp1
2/2 mice (P,0.05). Bone stiffness as determined by 3-point bending
was significantly reduced in Enpp1
2/2 tibiae and femurs from 22-week-old mice (P,0.05). Circulating phosphate and
calcium levels were reduced (P,0.05) in the Enpp1
2/2 null mice. Plasma levels of osteocalcin were significantly decreased at
6 weeks of age (P,0.05) in Enpp1
2/2 mice, with no differences noted at 22 weeks of age. Plasma levels of CTx (Ratlaps
TM)
and the phosphaturic hormone FGF-23 were significantly increased in the Enpp1
2/2 mice at 22 weeks of age (P,0.05). Fgf-
23 messenger RNA expression in cavarial osteoblasts was increased 12-fold in Enpp1
2/2 mice compared to controls. These
results indicate that Enpp1
2/2 mice are characterized by severe disruption to the architecture and mineralization of long-
bones, dysregulation of calcium/phosphate homeostasis and changes in Fgf-23 expression. We conclude that NPP1 is
essential for normal bone development and control of physiological bone mineralization.
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Introduction
Bone development and remodelling throughout life occurs
through a tightly controlled balance of osteoblastic bone formation
and resorption by osteoclasts. Bone formation during development
and the remodeling cycle are a result of the secretion of proteins of
the bone extracellular matrix (ECM), or osteoid and its
mineralization in a two-stage process. Primary mineralization is
a rapid phase where 70% of complete mineralization occurs. In
contrast, secondary mineralization occurs more slowly and is
characterized by a gradual maturation of the mineral and is
essential for the hardness and rigidity that enables the skeleton to
resist gravitational and mechanical loading. During the resorption
phase of the remodeling cycle, osteoclasts through acid production
and protease secretion induce demineralization and degradation of
the bone matrix [1,2].
Mineralization is initiated within osteoblast- and chondrocyte-
derived matrix vesicle (MVs) where Ca
2+ ions and inorganic
phosphate (Pi) crystallize to form hydroxyapatite (HA) [3]. The
MVs then release HA into the ECM, where further crystal growth
occurs [4,5]. The mineralization process depends on a regulated
balance of various physiochemical and protein inducers and
inhibitors. Physiochemical factors include calcium concentrations
and pH, as well as the regulation of ECM mineralization inhibitors
such as inorganic pyrophosphate (PPi), and inducers such as in
inorganic phosphate (Pi). The ratio of Pi to PPi controls the
deposition of bone mineral and concentrations of these factors are
regulated by tissue-non-specific alkaline phosphatase (TNAP),
ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) and
the ankylosis protein (ANK) [6–10]. In addition ECM proteins,
such as dentin matrix protein 1 (DMP1) [11], matrix gla protein,
osteopontin (OPN) [12–14] and phosphate regulating endopepti-
dase homolog, X-linked (PHEX) [15], play important roles in
regulating the mineralization process. Furthermore, primary
alterations in bone mineralization in hereditary hypophosphate-
mic disorders caused by mutations of Phex and Dmp1 as well as
mutations of Enpp1 [16,17] and Ank [18] have been associated with
increased circulating levels of the bone-derived phosphaturic
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metabolism is linked to systemic phosphate homeostasis.
NPP1 (EC 3.1.4.1) is a plasma membrane glycoprotein that
ectoplasmically generates PPi, a recognised inhibitor of HA crystal
formation [19], from nucleoside triphosphates [20]. Intracellular
to extracellular channelling of PPi is mediated by ANK [21,22].
Extracellular PPi concentration is regulated by TNAP, which
hydrolyzes PPi in the ECM to release Pi and establishing a Pi/PPi
ratio permissive for the formation of HA crystals [23–26]. Further
feedback signalling allows mediation of the mineralization process;
both Pi and PPi inhibits the enzymatic activity of TNAP [19], and
both exogenous Pi and PPi induce osteopontin (OPN) [7,9,19]. It
has been widely reported that lack of NPP1 function is associated
with a reduction in levels of circulating PPi [7,27,28].
Vascular calcification is a highly regulated cellular process
similar to skeletal mineralization [29,30]. By maintaining high
levels of extracellular PPi soft tissues, particularly vascular cells and
articular cartilage, can suppress spontaneous calcification [31]. In
human infants, severe NPP1 deficiency is associated with a
syndrome of spontaneous infantile arterial and periarticular
calcification [32,33]. Elevated levels of FGF-23, an inhibitor of
renal Pi re-absorption, have been observed in patients suffering
from hypophosphatemic rickets as a result of a loss of function
mutation in the NPP1 gene. This indicates that NPP1 may also
have a significant role in phosphate homeostasis [17].
In naturally occurring mouse models, the link between defective
NPP1 expression and altered mineralization was initially demon-
strated in ‘‘tiptoe walking’’ (ttw/ttw) mice. These animals are
homozygous for a GRT substitution resulting in the introduction
of a stop codon in the NPP1 coding sequence. The subsequent
truncated protein leads to the loss of a vital calcium binding
domain and two putative glycosylation sites [34]. The ttw/ttw
mouse phenotype includes the postnatal development of progres-
sive ankylosing intervertebral and peripheral joint hyperostosis, as
well as spontaneous arterial and articular cartilage calcification
and increased vertebral cortical bone formation [34–38]. Trans-
genic mice that are homozygous for a disruption in Exon 9 of the
Enpp1 gene exhibit abnormalities that are almost identical to those
present in naturally occurring ttw/ttw mice [27]. These include
decreased levels of extracellular PPi, with phenotypic features
including significant alterations in bone mineralization in long
bones and calvariae, and pathologic, severe peri-spinal soft tissue
and arterial calcification [7,9,28].
To date the examination of the role of NPP1 in bone function
has been limited to the study of immature 10-day-old mice [28].
However, little is known about its role in the maintenance of the
skeleton during the aging process. Therefore, we have studied
juvenile and adult mice to determine the effects of NPP1 on
skeletal maturation, which may not be apparent in the immature
developing skeleton. These studies have confirmed that the
structural and mechanical properties of the Enpp1
2/2 adult
skeleton are more severely compromised than their juvenile
counterparts. Furthermore, our analysis of Enpp1
2/2 mice
discloses an increase in circulating FGF-23 and Fgf-23 mRNA
expression in the calvaria indicating a possible role for Enpp1 in
phosphate regulation, a finding consistent with recent human
genetic studies [16,17,39].
Materials and Methods
Maintenance of Enpp1
2/2 mice
The generation and characterization of Enpp1
2/2 mice has
been previously described [33]. Genotyping was done on genomic
DNA isolated from ear clips and analyzed using PCR protocols
developed by Genetyper (Genetyper, New York, USA). Male and
female mice were culled at 6 weeks (juvenile) and 22 weeks (adult)
of age; gender and number of mice studied are specified in each
individual experiment. All animal experiments were approved by
The Roslin Institute’s Animal Users Committee and the animals
were maintained in accordance with UK Home Office guidelines
for the care and use of laboratory animals.
Gross analysis
Following euthanasia of male and female knockout (Enpp1
2/2)
and wild-type mice at 6 and 22 weeks of age, body length (crown –
rump) and body weight measurements were recorded (n=8).
Radiographic assessment of the left hind-limb was made from X-
ray images (Faxitron, Wheeling, IL, USA). Thereafter, femur and
tibia length and width were measured using DigiMax digital
vernier callipers (R. S. Components Ltd, Corby, Northants, UK).
Preparation of tissue for microscopical analysis
Heart, aorta and kidney were fixed in 10% neutral buffered
formalin (NBF), embedded in paraffin wax and 4 mM thick
sections were stained with H&E, alizarin red and von Kossa to
assess calcification status. Similarly, long bones and femorotibial
and talocrural joints were fixed in 10% NBF and either decalcified
in 10% EDTA for 14 days at 4uC and embedded in ax or directly
embedded in methyl-methacrylate (MMA) according to standard
procedures. Longitudinal plastic sections were cut at 5 mm using a
Leica microtome.
RNA isolation and RT-qPCR analysis of Fgf-23 expression
Total RNA were extracted from homogenized calvarial bone
from 12-week-old mice using TRI Reagent (Molecular Research
Center, Cincinnati, OH) and then treated with RNase-free DNase
(Qiagen, Valencia, CA). First-strand cDNA was synthesized using
iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). Total RNA
(1 mg) was used in each 20 ml reverse transcriptase reaction. The
iCycler iQ Real-Time PCR Detection System and iQ SYBR
Green Supermix (Bio-Rad) were used for real-time quantitative
PCR analysis. The expression was normalized to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) in the same sample and
expressed as 100% of the control (wild-type). Sequences of primers
used for real-time quantitative RT-PCR of Fgf-23 were FGF23.fo-
ward CAC TGC TAG AGC CTA TTC and FGF23.reverse CAC
TGT AGA TAG TCT GAT GG, GAPDH Forward AAT GGG
GTG AGG CCG GTG CT and GAPDH Reverse GCA GTG
ATG GCA TGG ACT GTG GT.
Histomorphometric analysis
The width of the proximal growth plate of both tibiae and
femurs was determined using image analysis software (Nikon,
Kingston upon Thames, Surrey, UK) on toluidine blue stained
paraffin sections. Growth plate width was determined at 10
different points along the breadth of the growth plate in two
sections from each bone [40]. MMA embedded sections of the
tibiae taken from 22-week-old female wild-type (n=4) and
Enpp1
2/2 mice (n=4) were reacted for tartrate resistant acid
phosphatase (TRAcP) activity to visualize osteoclasts and coun-
terstained with aniline blue to visualize bone. For the analysis of
osteoblasts, sections were reacted for alkaline phosphatase activity
using Naphthol AS-MX Phosphate as substrate and Fast Violet B
salt (Sigma-Aldrich, Gillingham, UK). Sections were viewed using
a4 6 or 106 objective lens on a Zeiss Axioimager (Zeiss, Jena,
Germany) microscope and images of the proximal tibia were
captured using a QImaging Retiga 4000R camera. Osteoclast
Disrupted Mineralization in Enpp12/2 Mice
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software based on ImageJ (developed by Rob van ’t Hof).
Micro-computed tomography
Tibiae and femors were dissected from 6 and 22-week-old male
and female wild-type and Enpp1
2/2 mice and stored in distilled
water at 220uC (n=8). The bones were scanned using a micro-
computed tomography (mCT) system (Skyscan 1172 X-Ray
microtomograph, Aartselaar, Belgium) to evaluate trabecular
architecture and cortical bone geometry. High-resolution scans
with an isotropic voxel size of 5 mm were acquired (60 kV, 0.5 mm
aluminium filter, 0.5u rotation angle). Two images were averaged
at each rotation angle to reduce signal noise and improve the
accuracy of the BMD measurements. Scan time was approxi-
mately 30 min per bone. The scans were reconstructed using
NRecon software (Skyscan, Belgium). For each bone, a 1000 mm
section of the metaphysis was taken for analysis of trabecular bone,
using the base of the growth plate as a standard reference point. A
further 1500 mm below the base of the metaphysis section a
400 mm section of the mid-diaphysis was scanned for analysis of
cortical structure.
Noise in the reconstructed images was reduced by applying a
median filter (radius=1), and bone tissue was identified by
thresholding. The optimal threshold was determined from the
image histograms, and was set to exclude soft tissue, but to include
poorly mineralised bone. The same threshold was used in all
samples. The thresholded image was used as a mask to measure
the BMD of the bone structures, using the unfiltered image data as
input. For accurate calculation of BMD appropriate calibration of
the Skyscan CT analyser was carried out with known density
calcium hydroxyapatite phantoms.
The following parameters were analyzed using CTAn software
(Skyscan, Belgium); in trabecular bone, percent bone volume (%
BV/TV), trabecular number (Tb.N; /mm), bone mineral density
(BMD; g/cm
3), trabecular thickness (Tb.Th; mm), trabecular
separation (Tb.Sp) and structure model index (SMI) were
evaluated. In cortical bone, % BV/TV, BMD (g/cm
3), cortical
thickness, cross-sectional area (mm
2), percentage of closed pores
and polar moment of inertia (mm
4) were evaluated.
Mechanical testing
3-point bending for the determination of bone stiffness and
breaking strength was completed using a Lloyd LRX5 materials
testing machine (Lloyd Instruments, West Sussex, UK) fitted with
a 2 kN load cell [41]. Tibiae and femora from 6 and 22-week-old
male and female wild-type and Enpp1
2/2 mice (n=7) were tested
to fracture. The span was fixed at 5.12 mm for femora and at
6.95 mm for tibiae. The cross-head was lowered at 1 mm/min
and data were recorded after every 0.2 N change in load and
every 0.1 mm change in deflection. Failure and fracture points
were identified from the load-extension curve as the point of
maximum load and where the load rapidly decreased to zero,
respectively. The maximum stiffness was defined as the maximum
gradient of the rising portion of this curve, and the yield point was
the point at which the gradient reduced to 90% of this value. Both
values were calculated from a polynomial curve fitted to the rising
region of the load-extension curve in Sigmaplot (Systat Software
Inc., San Jose, USA).
Whole blood and plasma analysis
Immediately following euthanasia, blood samples from 22-
week-old wild-type and Enpp1
2/2 female mice (n=10) were
obtained by cardiac puncture and collected into lithium heparin
tubes from which whole blood and plasma samples were prepared.
Haematological analysis of whole blood samples was undertaken
using a Pentra 60 impedance haematology analyser (Horiba
Medical, Northampton, UK) for determination of red blood cell
count, packed cell volume, haemoglobin concentration, mean
corpuscular volume (MCV), mean corpuscular haemoglobin
concentration (MCHC) and white blood cell (WBC) count.
Differential WBC counts were carried out manually on
Wright’s-stained smears and the percentage and absolute number
of neutrophils, lymphocytes, monocytes, eosinophils and basophils
were recorded.
To determine difference in bone remodelling rates, bone
formation and resorption markers were measured in plasma
samples taken from male mice at 6 and 22 weeks of age (n=6).
This was done using a sandwich ELISA osteocalcin kit (Mouse
Osteocalcin EIA Kit; Biomedical Technologies Inc, Stoughton,
MA, USA) and a C-terminal telopoptides of type I collagen ELISA
kit (RatLaps TM, IDS, Boldon, UK) respectively, and performed
according to manufacturer’s instructions. Circulating FGF-23
levels were measured using an FGF-23 ELISA kit (Kainos
Laboratories Inc., Tokyo, Japan). Inorganic phosphate, creatine
kinase activity, TNAP activity, total protein, albumin, bile acids,
cholesterol, creatinine, alanine aminotransferase and non-esteri-
fied fatty acids were measured on an IL600 biochemistry analyzer
(Instrumentation Laboratory, Warrington, Cheshire, UK) using
standard photometric kit methods (Instrumentation Laboratory).
Total calcium, potassium and sodium were measured using the
IL600 ISE (Instrumentation Laboratory). Globulin concentration
was calculated by subtraction of the albumin from the total protein
concentration.
Statistical analysis
General linear model analysis, Student’s t-test, Mann-Whitney
non-parametric test and Pearson’s correlations were used to assess
thedata whereappropriate.Alldataareexpressedasthe mean +/2
S.E.M. Statisticalanalysiswasperformed usingMinitab 15(Minitab
Ltd, Coventry, UK), and confirmed using SPSS (IBM Software,
New York, USA). P,0.05 was considered to be significant.
Results
Enpp1
2/2 mice show reduced growth
Initial studies addressed whether Enpp1
2/2 mice displayed a
reduced growth phenotype resembling that previously reported for
10-day-old Enpp1
2/2 mice. At 6 weeks of age a significant
reduction in body weight was observed in both male (83.7%;
P,0.05) and female (87.7%; P,0.01) Enpp1
2/2 mice (Table 1). A
concomitant decrease in body length was also noted in male
(87.3%; P,0.01) and female (89.2%; P,0.01) Enpp1
2/2 mice
(Table 1). However, there were no significant differences in the
lengths of the tibiae or femora of 6-week-old Enpp1
2/2 mice
(Table 1). Normal long bone growth in juvenile Enpp1
2/2 mice
was also confirmed by growth plate width analysis, which was
similar in both Enpp1
2/2 and WT mice (data not shown). Detailed
analysis of 22-week-old mice indicated that male and female
Enpp1
2/2 mice were also significantly lighter (83.5%; P,0.001
and 65.7%; P,0.001 respectively) and shorter (91.7%; P,0.01
and 91.3%; P,0.01 respectively) (Table 1). The femurs of both
male and female 22-week-old Enpp1
2/2 mice were significantly
shorter than their WT counterparts (94%; P,0.05 and 96.1%;
P,0.01). Interestingly the length of the tibia in the male 22-week-
old Enpp1
2/2 mice was longer (103.1%; P,0.01), but there was
no change seen in the 22-week-old females. No differences in
femoral or tibial growth plate widths were observed at 22 weeks of
age (data not shown).
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2/2 mice
In order to understand more fully the physiological role of
NPP1 on skeletal development and pathological mineralization, a
detailed histological assessment of adult Enpp1
2/2 mice at 22
weeks of age was undertaken. Alizarin red and von Kossa staining
revealed abnormal soft tissue calcification in the coronary artery,
the medial layer of the ascending aorta, aortic arch and
brachiocephalic artery (Fig. 1A) and in the cortex of the kidney
(Fig. 1C) of Enpp1
2/2 mice, compared to WT controls (Fig. 1B
and 1D).
A striking hyperostosis (excessive bone growth) of the cervical
(Fig. 1E) and thoracic (Fig. 1G) vertebrae, and the interphalangeal
and femorotibial (Fig. 1I) joints was observed in Enpp1
2/2 mice
compared to their wild-type counterparts (Fig. 1F, 1H and 1J
respectively). Encroachment of bone lesions onto the spinal cord
was observed, and may contribute to the abnormal gait observed
in some Enpp1
2/2 mice. An increased presence of blood cells,
thinner articular cartilage, misshapen and disorganised heads of
the tibiae and femora and ectopic cartilage deposition were also
noted in the femorotibial joint of the Enpp1
2/2 mice (Fig. 1I).
Radiography of the hind-limb revealed increased mineralization of
the knee and ankle joints, with reduced mineralization of the
femur and tibia in the Enpp1
2/2 (Fig. 1K), compared to WT mice
(Fig. 1L). These data show that lack of NPP1 activity significantly
increases mineralization within the vertebrae and interphalangeal,
femorotibial and talocrural joints, and indicate a reduction in long
bone mineralization.
Enpp1
2/2 mice have reduced trabecular bone mass
Enpp1
2/2 mice have been reported to display reduced mineral
content in both the growth plate and adjacent bone, with a
reduction in bone volume fraction and trabecular thickness at 10
days of age [28]. We have now completed a comprehensive high-
resolution mCT analysis of the tibia and femur to extend these
observations by fully examining the effects of Enpp1 deficiency on
bone phenotype in male and female juvenile and adult mice.
Reduced bone volume in male Enpp1
2/2 mice was apparent in
the trabecular compartment of the tibia and femur at both 6 and
22 weeks of age. Enpp1
2/2 mice had significantly reduced BV/
TV, trabecular number and trabecular thickness compared to
wild-type controls (Table 2; Fig. 2). These differences were more
marked in the 22-week-old mice. Comparable changes were
observed in female Enpp1
2/2 mice (data not shown). The
structural model index (SMI), which quantifies the characteristic
form of a 3D structure in terms of amounts of plates and rods [42],
was also significantly higher in tibiae and femurs from male
Enpp1
2/2 mice (P,0.05), with comparable changes in female
mice (data not shown). This indicates that the trabeculae in
Enpp1
2/2 mice are less ‘plate-like’ and less connected (Table 2).
Trabecular BMD was unchanged in the Enpp1
2/2 mice. These
results confirm that juvenile and adult Enpp1
2/2 mice have
reduced trabecular bone and are consistent with previous reports
of an association of an osteopenic phenotype in mice with Enpp1
ablation [28].
Enpp1
2/2 mice have reduced cortical thickness
A significant reduction in cortical thickness was observed in the
femur (P,0.05) and tibia (P,0.001) of male Enpp1 null mice at 22
weeks of age (Table 3). Cortical thickness measured in 6-week-old
mice was reduced but only significant in the femur (P,0.05). The
cross-sectional area of cortical bone was also reduced in all
samples, reaching significance in 22-week-old femurs (P,0.01)
and tibiae (P,0.001). The polar moment of inertia (an estimate of
the ability of the structure to resist torsional loading) was decreased
in all samples but only significant in 6-week-old tibiae (P,0.05).
Similar results were observed in female mice (data not shown). The
percentage closed porosity (a measure of the connectivity of the
pores) in the cortical bone was also reduced in Enpp1
2/2 mice at
22 weeks of age in both femurs (P,0.05) and tibiae (P,0.001).
Interestingly, bone mineral density was significantly increased in
the femurs and tibia of 22-week-old Enpp1
2/2 mice (P,0.05).
However, given the reduction in cortical thickness and area, it is
possible that there is an overall reduction in the mineral content of
the cortex of the Enpp1
2/2 mouse.
The long bones of Enpp1
2/2 mice have reduced strength
and stiffness
Changes in bone architectural organization in Enpp1
2/2 mice
are likely to alter the biomechanical properties of the long bones.
In order to test this we carried out 3-point bending analysis to
determine maximum stiffness (Fig. 3A), yield (Fig. 3B) and
maximum load (Fig. 3C) of tibia and femur of 6 and 22-week-
old male Enpp1
2/2 mice and compared them to wild-type control
mice. At 6 weeks of age Enpp1
2/2 tibiae showed a significant
Table 1. Body weight, body length and long bone length taken at 6 week and 22 weeks of age from male and female and Enpp1
2/
2 and wild-type mice.
Sex
Age
(weeks) Genotype Body weight (g) Body length (cm) Femur length (mm) Tibia length (mm)
Female 6 Enpp1
+/+ 20.4 (0.5) 8.96 (0.12) 13.83 (0.01) 16.88 (0.07)
Enpp1
2/2 17.9 (0.5)** 7.99 (0.21)** 13.61 (0.17) 16.93 (0.09)
22 Enpp1
+/+ 32.1 (0.7) 9.92 (0.13) 16.11 (0.42) 18.85 (0.25)
Enpp1
2/2 21.1 (0.7)*** 9.06 (0.14)*** 15.47 (0.13)** 19.26 (0.13)
Male 6 Enpp1
+/+ 25.2 (0.6) 9.79 (0.12) 14.52 (0.15) 17.57 (0.19)
Enpp1
2/2 21.1 (1.1)* 8.55 (0.27)** 14.00 (0.25) 17.18 (0.19)
22 Enpp1
+/+ 31.0 (0.8) 9.72 (0.l8) 16.06 (0.16) 18.63 (0.11)
Enpp1
2/2 25.9 (1.0)*** 8.91 (0.15)** 15.09 (0.59)* 19.21 (0.23)**
Data are presented as mean +/2 SEM (n=10). Significance is denoted by
*P,0.05,
**P,0.01.
***P,0.001.
doi:10.1371/journal.pone.0032177.t001
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although there was a reduction in maximum load this did not
reach significance. The changes in the 6-week-old femora were
more marked with significant decreases in maximum stiffness,
yield and maximum load (P,0.01). There were similar decreases
observed in mice at 22 weeks of age; analysis of the tibiae showed a
significant reduction in all parameters tested (P,0.05), whilst the
femora showed a significant reduction in maximum stiffness and
yield (P,0.05), but a more substantial change in maximum load
(P,0.001). The reduced resistance to bending observed in the
Enpp1
2/2 tibiae and femora is consistent with the reduced cortical
bone area and thickness revealed by the mCT analysis. 6-week-old
male femurs showed a significant correlation between both cortical
thickness and cortical area versus all 3-point bending parameters
(P,0.05). A significant correlation between cortical area and
maximum load (P,0.05) was observed in 22-week-old femurs.
Similarly 6-week-old tibiae showed significant correlations be-
tween cortical thickness and both yield and maximum stiffness
(P,0.05). However, 22-week-old tibiae showed no correlation
between mCT parameters and 3-point bending data. Furthermore,
no significant correlations were noted between mechanical
parameters and polar moment of inertia.
Plasma biochemical markers reflect the reduced bone
mass observed in Enpp1
2/2 mice
The level of osteoblast and osteoclast activity was assessed by
ELISA analysis on serum taken from 6 and 22-week-old male
Enpp1
2/2 and wild-type mice. Reduced plasma concentration of
osteocalcin, a marker of bone formation, was observed in the male
Enpp1
2/2 mice at 6 weeks of age (96%; P,0.05) (Fig. 4A). By 22
weeks of age, plasma concentrations of osteocalcin had dropped to
baseline levels in all mice. It was therefore difficult to observe any
potential differences between genotypes in the already low
osteocalcin levels observed in the mature animals. Plasma
concentrations of CTx, a marker of bone resorption, were
unchanged at 6 weeks of age. Interestingly, a reduction in CTx
levels, possibly due to a reduction in resorptive activity associated
with the cessation of growth, was observed in 22-week-old WT
mice. However, the 22-week-old Enpp1
2/2 mice did not show this
age dependent reduction in CTx levels, and therefore CTx levels
in these mice were significantly higher than their WT counterparts
(354%; P,0.05) (Fig. 4B). These results suggest that the reduced
bone mass observed in the trabecular compartments of the tibia
and femur are associated with reduced bone formation in juvenile
Enpp1
2/2 mice and a maintained level of bone resorption in the
adult Enpp1
2/2 mice.
Changes in circulating FGF-23 have been observed in humans
with mutant Enpp1 gene. To determine whether the lack of NPP1
activity had an effect on circulating FGF-23 in mice we carried out
an ELISA analysis on serum samples taken from 6 and 22-week-
old male Enpp1
2/2 and wild-type mice. These data showed that
there was a significant increase in circulating FGF-23 at both 6
and 22 weeks of age (P,0.05; Fig. 4C), confirming that there is a
Figure 1. Histological and radiographic assessment of tissues
from wild-type and Enpp1
2/2 mice. Calcification of the tunica
media of the aorta was detected by alizarin red staining (arrows) in (A)
Enpp1
2/2 compared to (B) wild-type control tissue. Ectopic calcification
of the kidney was detected by von Kossa staining (arrow) in (C) Enpp1
2/2
compared to (D) wild-type control tissue. H&E stained transverse section
of the neck of the (E) Enpp1
2/2 mouse showing an enlarged cervical
vertebra and increased deposition of cartilage (arrows) compared to the
(F) wild-type mouse. H&E stained longitudinalsectionof the mid-thoracic
vertebrae of the Enpp1
2/2 mouse (G) showing a severely increased
deposition of cartilage in the connective tissue and incursion into the
spinal cord (arrows) compared to the (H) wild-type mouse. H&E stained
sagittal section of the femorotibial joint of the (I) Enpp1
2/2 mouse
showing remodelling of the femur and over-growth of ectopic cartilage
(arrows) compared to the (J) wild-type mouse. Radiographs demonstrate
calcification of the femorotibial and tarsocrural joint (asterisk), and
reduced mineralization in the tibia and femur (arrows) of Enpp1
2/2 mice
(K) compared to wild-type control (L).
doi:10.1371/journal.pone.0032177.g001
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expression is increased in bone of other mutations of genes
affecting mineralization, including Phex, Dmp1 and Ank.T o
determine if the increased circulating FGF-23 levels were due to
increased Fgf-23 gene transcription in Enpp1
2/2 mice, we
quantified Fgf-23 mRNA expression by RT-qPCR. We found
that Fgf-23 mRNA expression in calvarial osteoblasts was 12-fold
greater in Enpp1
2/2 mice compared to wild-type littermates
(Fig. 4D).
A detailed analysis of plasma biochemistry was undertaken on
samples taken from female Enpp1
2/2 mice at 22 weeks of age.
Significant reductions in circulating levels of calcium (7%; P,0.05)
and Pi (16%; P,0.01) were observed in Enpp1
2/2 mice, which
may be a consequence of increased FGF-23 expression dysregulat-
Figure 2. 3D reconstruction of the trabecular bone scanned using microCT. (A) Wild-type and (B) Enpp1
2/2 mice femurs were collected at i)
6 weeks and ii) 22 weeks of age. These reconstructions illustrate the reduction of trabecular number in the Enpp1
2/2 mice.
doi:10.1371/journal.pone.0032177.g002
Table 2. MicroCT analysis of trabecular bone in male wild-type and Enpp1
2/2 mice.
Bone
Age
(weeks) Genotype % BV/TV BMD (g/cm
3)
Trab.
Thickness (mm)
Trab. Number
(TbN/mm)
Structural
Model Index
Tibia 6 WT 19.75 (1.82) 1.04 (0.02) 40.81 (1.68) 0.0049 (0.0005) 1.60 (0.06)
Enpp1
2/2 12.53 (2.26)* 1.07 (0.03) 38.93 (1.97) 0.0032 (0.0005)* 1.85 ( 0.16)
22 WT 14.46 (3.53) 1.17 (0.02) 53.84 (1.31) 0.0026 (0.0006) 1.93 (0.20)
Enpp1
2/2 4.78 (0.73)* 1.21 (0.02) 46.92 (1.08)*** 0.001 (0.0002)* 2.52 (0.09)**
Femur 6 WT 28.26 (2.55) 1.04 (0.01) 45.91 (1.69) 0.0062 (0.0006) 0.98 (0.16)
Enpp1
2/2 16.08 (1.87)** 1.05 (0.01) 40.73 (1.31)* 0.0039 (0.0004)** 1.53 (0.19)*
22 WT 15.09 (2.28) 1.12 (0.01) 53.34 (1.32) 0.0028 (0.0004) 1.85 (0.08)
Enpp1
2/2 4.75 (0.64)*** 1.16 (0.02) 46.92 (1.52)** 0.001 (0.0001)*** 2.54 (0.04)***
6 week femur (WT and Enpp1
2/2 n=7) and tibia (WT n=6, Enpp1
2/2 n=7) and 22 week femur (WT and Enpp1
2/2 n=9) and tibia (WT and Enpp1
2/2 n=9) were tested.
SEM is shown in brackets, significance is denoted by
*P,0.05,
**P,0.01.
***P,0.001.
doi:10.1371/journal.pone.0032177.t002
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(116%; P,0.01) was observed in Enpp1
2/2 mice, suggesting a
compensatory mechanism to increase bone formation in the
absence of NPP1. No effect of genotype on levels of total protein,
albumin, globulin, potassium, sodium, bile acids, cholesterol,
creatinine, alanine aminotransferase or non-esterified fatty acids
were recorded (Table 4). A significant increase in plasma creatine
kinase activity (239%; P,0.05; Table 4), a known marker of
muscle degradation, was noted.
Given that expression of NPP1 has been observed in
macrophages [43], analysis of whole blood samples was under-
taken to determine whether Enpp1 ablation is associated with an
altered hematological profile. No significant differences were
recorded in the number of platelets, lymphocytes, monocytes,
neutrophils or eosinophils in the peripheral blood of Enpp1
2/2
mice (data not shown). Therefore these data indicate that the
severe phenotypic abnormalities observed in the Enpp1
2/2 mice
do not impact on the hematological profile.
Histomorphometric analysis shows no change in
osteoclast number
Histomorphometric analysis carried out on the tibiae of 22-
week-old mice corroborated the mCT data showing a significant
reduction in %BV/TV (Enpp1
2/2: 2.2+/20.59; wild-type: 5.96+/
21.02; P,0.05, n=4). No significant difference in osteoclast
surface/bone surface (Enpp1
2/2: 31.42%+/25.3; wild-type:
20.69%+/22.7) or osteoclast number (Enpp1
2/2: 46.63+/28.6;
wild-type: 44.4+/26.8) was observed in Enpp1
2/2 mice. This
suggests that the increase in resorption measured by the CTx assay
(Fig. 4B) may be due to a greater level of osteoclast activity rather
than an increase in osteoclast numbers. Interestingly, a significant
increase in osteoblast surface/bone surface (Ob.S/BS) was seen
when 22-week-old Enpp1
2/2 (39.6+/27.8) and wild-type (14.7+/
21.8) mice were compared (n=4; p,0.05). When considered
together with the osteocalcin ELISA data (Fig. 4A) these data
suggest that there is impaired osteoblast function in the Enpp1
2/2
mice.
Discussion
Impaired HA deposition results in bone frailties such as
osteomalacia, rickets and hypophosphatasia. The latter is an
inborn-error-of-metabolism, which results from hypomorphic
mutations in the TNAP gene, and provides the best evidence of
the importance of TNAP for bone mineralization [44]. This lack
of TNAP activity results in an excess of its substrate, PPi, which is a
recognised inhibitor of the mineralization process [19]. Conversely
a deficiency in PPi results in ectopic calcification and soft tissue
mineralization [7,28]. Mice lacking NPP1 have severe minerali-
zation defects, which are associated with abnormally low PPi levels
[7,27,28]. These mice (Enpp1
2/2) are, therefore, a valuable tool
with which to understand more fully the role of NPP1 in
controlling physiological and pathological mineralization. This
present study represents the first detailed evaluation in the adult
mouse of the dramatic effects of Enpp1 ablation on soft tissue
calcification and hyperstosis of vertebrae and joints. These data
confirm and extend previous reports [9,45–47], and support the
role of NPP1 as a critical regulator of mineralization through the
production of PPi [28,47].
Our data indicate that Enpp1
2/2 mice have reduced
trabecular bone mass and cortical thickness of both the tibia
and femur. These changes in bone architecture are consistent
with altered markers of bone formation and resorption and
explain reduced mechanical properties. This is likely to be a
direct effect of lack of NPP1 activity, but the noted reduction in
body weight will reduce the loading on the bones and thus may
have an effect on their structure. Of particular interest was our
observation that by 22 weeks of age the male Enpp1
2/2 mice had
shorter femurs but longer tibiae compared to wild-type controls.
This opens the possibility that changes in structure due to
different effects of loading may be occurring, and requires
further investigation.
Interestingly, a small but significant increase in cortical BMD was
observed at 22 weeks of age in the femur and tibia of Enpp1
2/2
mice. This increased BMD appears to be a result of a reduction in
cortical thickness. This trait appears to be age dependent as BMD
was normal in 10 day old Enpp1
2/2 mice [28] and similarly BMD
and cortical thickness were unaltered in the long bones of 6 week-
old Enpp1
2/2 mice of this present study. It may also be worth
considering that as the Enpp1
2/2 mice show mineralization of the
vasculature, thus the increase of cortical BMD and percentage
closed porosity may be influenced by mineralization of the vessels
within the pores of the cortical bone. Further studies are required to
address this.
Table 3. MicroCT analysis of cortical bone in male wild-type and Enpp1
2/2 mice.
Bone
Age
(weeks) Genotype % BV/TV BMD (g/cm
3)
Cortical
Thickness (mm)
Cortical Area
(mm
2)
Closed
Porosity (%)
Polar Moment of
Inertia (mm
4)
Tibia 6 WT 88.19 (1.98) 1.15 (0.02) 18.46 (0.36) 0.825 (0.016) 0.087 (0.025) 0.717 (0.037)
Enpp1
2/2 90.52 (0.39) 1.18 (0.004) 18.44 (0.54) 0.707 (0.055) 0.094 (0.030) 0.512 (0.072)*
22 WT 98.6 (0.16) 1.31 (0.01) 32.00 (0.34) 1.01 (0.034) 0.113 (0.012) 0.777 (0.06)
Enpp1
2/2 98.36 (0.10) 1.33 (0.01)* 28.99 (0.43)*** 0.778 (0.028)*** 0.035 (0.005)*** 0.615 (0.043)
Femur 6 WT 93.19 (0.62) 1.21 (0.01) 23.21 (0.41) 0.986 (0.048) 0.091 (0.025) 0.333 (0.037)
Enpp1
2/2 92.16 (0.44) 1.20 (0.01) 21.41 (0.59)* 0.881 (0.13) 0.069 (0.012) 0.249 (0.032)
22 WT 98.99 (0.09) 1.38 (0.01) 39.54 (1.05) 0.986 (0.025) 0.058 (0.007) 0.297 (0.046)
Enpp1
2/2 99.11 (0.14) 1.41 (0.01)** 37.08 (0.62)* 0.865 (0.028)** 0.034 (0.004)* 0.284 (0.354)
6 week femur (WT n=7, Enpp1
2/2 n=6) and tibia (WT n=6, Enpp1
2/2 n=7) and 22 week femur (WT and Enpp1
2/2 n=9) and tibia (WT n=8, Enpp1
2/2 n=9) were
tested. SEM is shown in brackets, significance is denoted by
*P,0.05,
**P,0.01.
***P,0.001.
doi:10.1371/journal.pone.0032177.t003
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old Enpp1
2/2 and [Enpp1
2/2; Akp2
2/2] double knockout mice
indicated that the effects of Enpp1 ablation on an Akp2 null
background is site-specific [28]. Thus, in contrast to the
normalization of the degree of mineralization seen in the joints,
calvaria, vertebrae and soft tissues as a consequence of ablating
both NPP1 and TNAP function, the long bones of these double
knockout mice appeared to remain hypomineralized. This study
suggested that hypomineralization observed in the tibia and femur
of Enpp1
2/2 mice may be related to relatively low levels of
endogenous NPP1 expression throughout the long bones when
compared to the calvaria [28]. Thus, in long bones, the complete
deletion of NPP1 activity would further reduce extracellular PPi to
abnormally low levels. This would result in insufficient PPi
substrate for TNAP to generate Pi for normal mineral formation.
Interestingly, it has recently been shown that NPP1 can regulate
osteoblastic gene expression, and control cellular differentiation, in
calvarial osteoblasts independent of PPi and Pi [48]. Histomor-
phometric analysis indicated that there was a significant increase
in osteoblast surface/bone surface in tibiae of Enpp1
2/2 mice. In
spite of the increase in osteoblast surface, osteocalcin levels were
similar to those in WT mice, suggesting that disruption of Enpp1
decreases the activity of individual osteoblasts. Furthermore, an
accumulation of nucleotide triphosphates due to lack of hydrolysis
by NPP1 [49] may have a downstream affect on bone remodelling
through purinergic signalling [50].
Figure 3. 3-point bending shows a reduction in mechanical strength of long bones. Values are shown for tibias and femurs taken from
wild-type and Enpp1
2/2 mice at 6 weeks and 22 weeks of age. (A) Maximum stiffness was calculated from the point of maximum gradient of a
polynomial curve fitted to the load-extension curve. (B) Yield is the point at which the gradient is reduced to 90% of the maximum stiffness. (C)
Maximum load was defined as the highest point on the Load-extension curve. Error bars show SEM, significance is denoted by * P,0.05, ** P,0.01
*** P,0.005.
doi:10.1371/journal.pone.0032177.g003
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e32177We also provide further evidence for the severe hyperminer-
alization of the soft tissues including significant arterial calcifica-
tion in adult Enpp1
2/2 mice. Notably, significant deposition of
calcium in the cortex of the kidney was observed for the first time.
These studies also showed that Enpp1
2/2 mice had severe
hyperostosis of the vertebrae and disorganisation and excessive
bone production in the femorotibial joint. These data are
consistent with previous reports of an association of an osteopenic
phenotype with Enpp1 ablation, where hypermineralization of the
soft tissue, and certain skeletal sites, was observed [28]. This study
went on to show that calcified nodule formation and mineral
deposition are inhibited to a higher extent in osteoblasts isolated
from Enpp1
2/2 bone marrow than calvarial osteoblasts isolated
from the same animal. This indicates that loss of NPP1 activity
affects skeletal sites in a site-specific manner [28].
As NPP1 is known to be important mediator of insulin signalling
in various tissue types including adipose and muscle [51], the
effects of glucose regulation may also contribute to the
hypomineralization observed in the long bones. Our data show
that Enpp1 null mice display significantly reduced body weight in
juvenile and adult mice. Long bone lengths and growth plate
widths were unchanged at 6 weeks of age but a significant
reduction in body weight was observed in these mice. This may
indicate reduced fat accumulation associated with increased
insulin sensitivity in mice lacking NPP1, given the previously
reported observations of insulin resistance and glucose intolerance
in mice with over-expression of hepatic NPP1 [52]. Furthermore,
administration of calcitonin to the ttw/ttw mouse ameliorates the
osteopenic effect. Calcitonin’s main biological function is to inhibit
osteoclast activity [53]. This suggests that in ttw/ttw mice - and
possibly Enpp1
2/2 mice, given the observed increase in circulating
CTx - a state of increased osteoclastic activity leads to bone loss at
certain sites. This increased osteoclastic activity could in turn lead
to increased osteocalcin decarboxylation, favouring pancreatic
beta cell proliferation, insulin secretion, insulin sensitivity and
energy expenditure [54,55]. The regulation of insulin signalling in
bone by NPP1 requires further investigation.
Our data show that Enpp1
2/2 mice maintain similar levels of
osteoclast activity at 6 and 22 weeks of age, whereas WT mice
show reduced bone resorption with advancing age which is
consistent with the attainment of the adult skeleton. Surprisingly
we do not see a concomitant rise in osteoclast number or osteoclast
surface/bone surface, indicating an upregulation of osteoclast
function. We have also described an increase in circulating levels
of creatine kinase, a cytoplasmic enzyme released during tissue
turnover. This is most likely to be due to skeletal muscle disruption
in the areas of hyperostosis. However, it has been reported that the
presence of brain-type creatine kinase (Ckb) is greatly increased
during osteoclastogenesis and that reduction in Ckb expression
using RNAi technology resulted in reduced bone loss in both rat
and mouse models [56]. Furthermore, the presence of creatine
kinase in matrix vesicles isolated from femurs of chicken embryos
suggests it has an active role in bone mineralization [57]. These
studies suggest that osteoclast function in the Enpp1
2/2 mice may
be affected by an increase in creatine kinase levels.
Elevated FGF-23 circulating levels and expression in bone adds
to a growing number of single gene mutations whose activation
impairs bone mineralization and leads to increments in Fgf-23
gene transcription [58]. FGF-23 is known as a phosphaturic
hormone that controls phosphate homeostasis, calcium homeo-
stasis and bone mineralization. FGF-23 binds to FGF receptors
(mainly FGFR1) and the co-receptor KLOTHO in the kidney and
promotes excretion of Pi, which leads to reduced serum Pi [59,60]
and stimulation of Cyp24 and inhibition of Cyp27b1 in the kidney
to reduce circulating 1,25(OH)2D levels. Therefore the decreases
in circulating calcium and phosphate levels in Enpp1
2/2 mice are
consistent with excess FGF-23. Regardless, our findings in
Enpp1
2/2 mice are consistent with human genetic studies that
have recently shown that Enpp1, if mutated, causes hypophospha-
temic rickets resulting from increased FGF-23 levels [17]. The
mechanism whereby Fgf-23 gene transcription in bone is
stimulated by Enpp1 inactivation is not defined by our studies,
however, recent data indicate alterations in matrix mineralization
caused by other single gene mutations in osteoblasts leads to
stimulation of Fgf-23 expression via FGF receptor activation [61].
Further studies will be needed to determine if the increase in FGF-
23 observed in Enpp1
2/2 bone is intrinsic and due to pathways
similar to Phex and Dmp1 mutations [11,15] or as a result of distinct
signalling pathways. Observed increases in serum FGF-23 levels
may regulate the Enpp1
2/2 bone phenotype through the bone-
kidney axis or through local effects on bone cells. There is also
controversial evidence that FGF-23 may directly affect skeletal
mineralization, independent of phosphate homeostasis [62], which
further confounds the interpretation of the bone phenotype in
Enpp1
2/2 mice. Alternatively, reductions in PPi concentrations,
the precursor to Pi, could result in local reductions in Pi
concentrations in the extracellular matrix required for normal
mineralization. More detailed studies examining the roles of
Table 4. Measurements taken of blood serum biochemistry
of female 22 week old wild-type and Enpp1
2/2 mice.
Analyte WT Enpp1
2/2
Calcium (mmol/L) 2.31 (0.05) 2.15 (0.05)*
Inorganic phosphate (mmol/L) 2.42 (0.06) 2.03 (0.10)**
Alkaline phosphatase (IU/L) 38.11 (5.65) 82.50 (12.28)**
Creatine kinase (IU/L) 271.22 (34.30) 919.40 (278.89)*
Sodium (mmol/L) 151.0 (0.75) 150.5 (2.05)
Potassium (mmol/L) 8.00 (0.29) 9.45 (0.60)
Non-esterified fatty acids (mmol/L) 0.92 (0.20) 1.05 (0.07)
Total protein (g/L) 51.82 (1.43) 56.95 (2.09)
Albumin (g/L) 28.72 (1.07) 30.13 (0.85)
Globulin (g/L) 23.10 (0.53) 26.82 (1.84)
Bile acids (mmol/L) 80.28 (36.78) 53.31 (19.32)
Cholesterol (mmol/L) 2.11 (0.30) 2.15 (0.18)
Creatinine (mmol/L) 43.78 (1.41) 41.9 (0.97)
Glucose (mmol/L) 10.39 (0.54) 10.88 (0.57)
SEM is shown in brackets, significance is denoted by
*P,0.05,
**P,0.01.
*** P,0.005.
doi:10.1371/journal.pone.0032177.t004
Figure 4. Levels of serum markers and mRNA. (A) Osteocalcin, a marker of bone formation, (B) CTx (RatLaps TM), a marker of bone resorption,
and (C) FGF-23 were measured by ELISA in serum samples taken from wild-type and Enpp1
2/2 mice at 6 weeks and 22 weeks of age. (D) Fgf-23 mRNA
expression was assessed by RT-qPCR in calvarial bone of wild-type and Enpp1
2/2 mice at 12 weeks of age. Error bars show SEM, significance is
denoted by *P,0.05, ** P,0.01 *** P,0.005.
doi:10.1371/journal.pone.0032177.g004
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2/2 mice
through local or systemic effects are needed.
In summary, our data demonstrate that Enpp1
2/2 mice are
characterized by severe disruption to the structural and mechan-
ical properties of long bones, the severity of which increases with
age. Furthermore, dysregulation of calcium/phosphate homeosta-
sis and hypercalcification in joints and soft tissues confirms that
NPP1 plays important roles in calcium and phosphate regulation
and repression of soft tissue mineralization, as well as maintaining
skeletal structure and function.
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